Difference between revisions of "Bexarotene (Targretin)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - " " to " ") |
Warner-admin (talk | contribs) m (Text replacement - "chemocare.com/chemotherapy/drug-info" to "chemocare.com/druginfo") |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 12: | Line 12: | ||
*[http://targretin.com/pdf/CAPS-PI-Jan18.pdf Bexarotene (Targretin) capsules package insert]<ref name="insert"></ref> | *[http://targretin.com/pdf/CAPS-PI-Jan18.pdf Bexarotene (Targretin) capsules package insert]<ref name="insert"></ref> | ||
*[http://targretin.com/pdf/GEL-PI-Jan-18.pdf Bexarotene (Targretin) gel package insert]<ref name="insert_gel"></ref> | *[http://targretin.com/pdf/GEL-PI-Jan-18.pdf Bexarotene (Targretin) gel package insert]<ref name="insert_gel"></ref> | ||
| − | *[https://chemocare.com/ | + | *[https://chemocare.com/druginfo/bexarotene.aspx Bexarotene systemic (Targretin) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/bexarotene.aspx Bexarotene systemic (Targretin) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/bexarotene-systemic-patient-drug-information Bexarotene systemic (Targretin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/bexarotene-systemic-patient-drug-information Bexarotene systemic (Targretin) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/bexarotene-systemic-patient-drug-information Bexarotene systemic (Targretin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/bexarotene-systemic-patient-drug-information Bexarotene systemic (Targretin) patient drug information (UpToDate)]</ref> | ||
*[http://www.uptodate.com/contents/bexarotene-topical-patient-drug-information Bexarotene topical (Targretin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/bexarotene-topical-patient-drug-information Bexarotene topical (Targretin) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/bexarotene-topical-patient-drug-information Bexarotene topical (Targretin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/bexarotene-topical-patient-drug-information Bexarotene topical (Targretin) patient drug information (UpToDate)]</ref> | ||
| Line 20: | Line 20: | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
*2001-03-29: Initial authorization | *2001-03-29: Initial authorization | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2016-01-22: Initial approval for the treatment of [[cutaneous T-cell lymphoma]]. | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' | + | *'''Code name:''' LGD-1069 |
*'''Brand names:''' Bexgratin, Targretin | *'''Brand names:''' Bexgratin, Targretin | ||
| Line 36: | Line 38: | ||
[[Category:FDA approved in 1999]] | [[Category:FDA approved in 1999]] | ||
[[Category:EMA approved in 2001]] | [[Category:EMA approved in 2001]] | ||
| + | [[Category:PMDA approved in 2016]] | ||
Revision as of 23:39, 2 September 2023
General information
Class/mechanism: Retinoid, selectively binds and activates retinoid X receptor subtypes (RXRα, RXRβ, RXRγ), which allow them to function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. Exact mechanism of action in the treatment of cutaneous T-cell lymphoma (CTCL) is unknown.[1][2][3][4][5]
Route: PO, topical
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1][3]
Diseases for which it is used
Patient drug information
- Bexarotene (Targretin) capsules package insert[1]
- Bexarotene (Targretin) gel package insert[3]
- Bexarotene systemic (Targretin) patient drug information (Chemocare)[6]
- Bexarotene systemic (Targretin) patient drug information (UpToDate)[7]
- Bexarotene topical (Targretin) patient drug information (UpToDate)[8]
History of changes in FDA indication
- 1999-12-29: Initial approval for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. (Based on Duvic et al. 2001a & Duvic et al. 2001b)
History of changes in EMA indication
- 2001-03-29: Initial authorization
History of changes in PMDA indication
- 2016-01-22: Initial approval for the treatment of cutaneous T-cell lymphoma.
Also known as
- Code name: LGD-1069
- Brand names: Bexgratin, Targretin
References
- ↑ 1.0 1.1 1.2 Bexarotene (Targretin) capsules package insert
- ↑ Bexarotene (Targretin) capsules package insert (locally hosted backup)
- ↑ 3.0 3.1 3.2 Bexarotene (Targretin) gel package insert
- ↑ Bexarotene (Targretin) gel package insert (locally hosted backup)
- ↑ Targretin manufacturer's website
- ↑ Bexarotene systemic (Targretin) patient drug information (Chemocare)
- ↑ Bexarotene systemic (Targretin) patient drug information (UpToDate)
- ↑ Bexarotene topical (Targretin) patient drug information (UpToDate)